Metastatic Prostate Cancer Prognosis Calculator

Metastatic castration-resistant prostate cancer (mCRPC) represents the most advanced and lethal stage of prostate cancer. It is defined as prostate cancer that continues to progress — through rising PSA, new metastases, or symptomatic deterioration — despite castrate levels of serum testosterone (generally <50 ng/dL), achieved either through surgical or medical castration. Prognosis in mCRPC is highly variable, ranging from a few months to several years, and accurate prognostic stratification is essential for informed treatment decision-making, patient counselling, and clinical trial enrolment. The Halabi nomogram, developed by Susan Halabi and colleagues and published in the Journal of Clinical Oncology in 2003 using pooled data from CALGB (Cancer and Leukemia Group B) clinical trials, is one of the most widely validated prognostic tools for mCRPC. It uses pre-treatment clinical and biochemical variables that have been shown in multivariate analyses to be independently associated with overall survival. The variables included in the model are PSA level, Gleason score at diagnosis, ECOG performance status, presence of visceral metastases, haemoglobin, lactate dehydrogenase (LDH), and alkaline phosphatase. This calculator uses a simplified points-based approximation of the Halabi nomogram principles. PSA is scored on a log scale: levels above 20 ng/mL receive 2 points, levels between 4 and 20 receive 1 point, and levels at or below 4 ng/mL receive 0 points. Gleason score contributes 0 points for low-grade disease (2–6), 1 point for Gleason 7, and 2 points for high-grade disease (8–10). ECOG performance status contributes points equal to its numerical value (0, 1, or 2). Visceral metastases to liver, lung, or brain carry 2 points due to their strong association with poor prognosis. Haemoglobin contributes 0 points if ≥13 g/dL (normal), 1 point if 10–12.9 g/dL (mild anaemia), and 2 points if <10 g/dL (significant anaemia). Elevated LDH (>200 U/L) or elevated alkaline phosphatase (>120 U/L) each contribute 1 point. Patients are stratified into three risk groups: low risk (0–2 points) with estimated median survival of approximately 26 months; intermediate risk (3–5 points) with approximately 14 months; and high risk (6 or more points) with approximately 7 months. These estimates reflect historical data from clinical trial populations treated primarily with docetaxel-based chemotherapy, and actual survival for individual patients may differ substantially based on treatment received, comorbidities, and disease biology. This calculator is intended for educational and clinical orientation purposes only. It should not replace formal prognostic assessment by an oncologist, which incorporates additional clinical information, imaging, molecular profiling, and the rapidly evolving landscape of mCRPC treatments including androgen receptor signalling inhibitors, PARP inhibitors, lutetium-177-PSMA therapy, and novel immunotherapeutic combinations.